Skip to content

Zepbound for sleep apnea: what it is approved for and who covers it

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Zepbound for sleep apnea is an FDA-approved use: moderate to severe obstructive sleep apnea in adults with obesity. In the label's two 52-week sleep apnea studies, body weight changed by -17.7% and -19.6% with Zepbound versus -1.6% and -2.3% with placebo. CMS, which runs Medicare, says this use is coverable under Medicare Part D.

Source: Zepbound FDA label

Key takeaways

  • Zepbound is the only GLP-1 approved for sleep apnea, and only for moderate to severe obstructive sleep apnea in adults with obesity.
  • The label doesn't cover mild sleep apnea. Ask whether your sleep study meets its wording.
  • On Medicare, go through your Part D plan. You'd not qualify for Zepbound for sleep apnea under the GLP-1 Bridge.
  • Coverable doesn't mean automatic. Expect a prior authorization or formulary exception with your diagnosis documented.
  • If you have commercial insurance, ask whether Zepbound is covered for OSA and what paperwork the plan wants.

Zepbound is the only one of the eight FDA-approved GLP-1 medicines with a sleep apnea use on its label. That matters for two reasons. It gives people with obstructive sleep apnea and obesity an approved medicine, and it opens a coverage route that a weight-loss prescription alone doesn’t. This page covers both. For the medicine itself, see the Zepbound guide.

What the label says

The Zepbound label lists two approved uses. One is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition (a health problem linked to weight). The other is the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Read the second one closely, because each part is a condition:

  • Moderate to severe. The use doesn’t cover mild sleep apnea.
  • Obstructive. It names obstructive sleep apnea specifically.
  • Adults with obesity. The weight-reduction use extends to adults with overweight and a weight-related condition. The sleep apnea use says obesity.

How severity is measured and documented is a clinical matter for your prescriber and, usually, a sleep study.

As with its weight use, the label says to use Zepbound in combination with a reduced-calorie diet and increased physical activity. The label also says safety and effectiveness have not been established in pediatric patients. And it says taking it with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

Zepbound sleep apnea study results

The label reports two 52-week studies in sleep apnea, numbered Study 5 and Study 6. The results table is titled “Changes in Apnea-Hypopnea Index (AHI), Hypoxic Burden, and Body Weight at Week 52.” So the table reports sleep and breathing measures as well as weight.

Here are the body-weight rows of that table. Placebo means an inactive treatment.

  • Study 5: body weight changed by -17.7% with Zepbound (114 patients) versus -1.6% with placebo (120 patients).
  • Study 6: body weight changed by -19.6% with Zepbound (119 patients) versus -2.3% with placebo (114 patients).

The table labels the Zepbound groups “MTD (10 mg or 15 mg).” MTD stands for maximum tolerated dose.

The full table, including the AHI and hypoxic burden rows, is in section 14.2 of the prescribing information, which is linked in the sources below. Your prescriber can go through it with you.

Why the diagnosis changes Medicare coverage

Medicare Part D excludes drugs “when used for” weight loss. A Zepbound prescription written for weight management alone falls under that exclusion. A Zepbound prescription written for sleep apnea doesn’t.

CMS, which runs Medicare, says an anti-obesity medication is coverable in Part D when it’s used for another medically accepted indication, and it states that moderate to severe obstructive sleep apnea is an indication eligible for Part D coverage. It names this exact use, “Zepbound for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity,” as coverable under the basic Part D benefit “regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary.” A formulary is a plan’s list of covered drugs. Plans must follow their existing formulary exception processes for these requests.

That has three practical consequences:

  1. Your plan is the route, not the Bridge. CMS says a person prescribed Zepbound for sleep apnea would not qualify for it under the Medicare GLP-1 Bridge. The Bridge explainer covers that exclusion.
  2. Expect paperwork. “Coverable” doesn’t mean automatic. Your prescriber may need to submit a prior authorization (the plan’s approval before it pays) or a formulary exception with the diagnosis documented.
  3. Part D cost rules apply. A drug covered by your plan counts toward your deductible and the annual out-of-pocket cap, which Bridge fills do not. See Part D costs in 2026 and does Medicare cover Zepbound.

Commercial insurance and paying cash

Commercial plans write their own criteria. Ask your plan whether Zepbound is covered for OSA, and what paperwork it wants. If the plan covers Zepbound, the manufacturer’s savings card brings a fill to as little as $25, subject to its terms.

Without coverage, Zepbound self-pay through LillyDirect starts at $299 a month. It’s $449 a month for the 10 mg vial and $449 for the 15 mg vial when you refill on time. The self-pay price is the same whatever the diagnosis. The Zepbound cost page explains the refill-window rule behind those prices, and the cheapest path tool compares your routes.

Zepbound comes as a single-dose pen, a vial and a KwikPen. The label says patients should be told which form they’ll receive and be trained for it.

What is not approved for sleep apnea

  • Other GLP-1 brands. None of the other seven medicines lists a sleep apnea use, including Mounjaro, which also contains tirzepatide.
  • Retatrutide. Lilly’s Phase 3 program for retatrutide includes a trial in moderate-to-severe obstructive sleep apnea and obesity. Retatrutide is investigational, meaning still being studied, and is not FDA-approved for any use. See the pipeline page.

Questions for your prescriber

  1. Does my sleep study result meet the label’s “moderate to severe” wording?
  2. Will the prescription state sleep apnea as the reason, and will you submit the prior authorization or exception?
  3. How does Zepbound fit with the sleep apnea treatment I already use?
  4. Which dose does the label’s schedule lead to, and how long does it take? The titration schedule tool shows the steps.

Frequently asked questions

Is Zepbound FDA-approved for sleep apnea?

Yes. The Zepbound label lists moderate to severe obstructive sleep apnea (OSA) in adults with obesity as an approved use, alongside long-term weight reduction. The wording has two conditions built in: the sleep apnea must be moderate to severe, and the patient must be an adult with obesity.

Does Medicare cover Zepbound for sleep apnea?

It can. CMS states that moderate to severe obstructive sleep apnea is an indication eligible for Part D coverage. It names Zepbound for OSA in adults with obesity as a use coverable under the basic Part D benefit, whether or not the drug is on the plan's formulary (its list of covered drugs). Plans handle these requests through their formulary exception process.

Can I use the Medicare GLP-1 Bridge if I have sleep apnea?

No. CMS says people prescribed a GLP-1 for a use that's coverable under the basic Part D benefit would not qualify for that drug under the Medicare GLP-1 Bridge, and it gives Zepbound for moderate to severe obstructive sleep apnea as the example. The request goes to your Part D plan.

Is Mounjaro or Wegovy approved for sleep apnea?

No. Among the eight FDA-approved GLP-1 medicines, only Zepbound lists a sleep apnea use. Mounjaro also contains tirzepatide, but its label covers type 2 diabetes uses, and an approved use on one brand's label doesn't transfer to another brand.

How much weight did people lose in the Zepbound sleep apnea studies?

The label table reports body-weight change at week 52. In Study 5 it was -17.7% with Zepbound versus -1.6% with placebo, and in Study 6 it was -19.6% versus -2.3%. The table labels the Zepbound groups as MTD (10 mg or 15 mg), the maximum tolerated dose. These are trial averages, not a prediction for any one person.

Sources (16)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 14.2, Table 9
    “Table 9: Changes in Apnea-Hypopnea Index (AHI), Hypoxic Burden, and Body Weight at Week 52 in Study 5 and Study 6. Body weight (kg) - % change from baseline: Study 5 Placebo N = 120: -1.6; Study 5 ZEPBOUND MTD (10 mg or 15 mg) N = 114: -17.7; Study 6 Placebo N = 114: -2.3; Study 6 ZEPBOUND MTD (10 mg or 15 mg) N = 119: -19.6”
  2. 2.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
  3. 3.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  4. 4.
    FDA label (DailyMed): Zepbound prescribing information, section 8.4
    “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
  5. 5.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
  6. 6.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  7. 7.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  8. 8.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  9. 9.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  10. 10.
    CMS: Information for Part D Plans
    “Under the Medicare GLP-1 Bridge, participating manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply. Coverage of eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge is provided outside of the Part D benefit payment flow and coverage. As such, no part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC), and no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.”
  11. 11.
    Medicare.gov: How much does Medicare drug coverage cost?
    “After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
  12. 12.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.”
  13. 13.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use. [...] Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected.”
  14. 14.
  15. 15.
  16. 16.